INSULET CORP — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Insulet Corporation and Abbott Diabetes Care Inc. (ADC) executed Amendment No. 9 to their Amended and Restated Development and Commercialization Agreement, effective August 25, 2026. The amendment modified Exhibit 1.12 (Approved Designees); specific terms, financial amounts, and commercial impacts are redacted [***] as confidential. No dollar figures, percentages, or quantitative changes are disclosed.
Why this rating
Abbott partnership is material to Insulet, but amendment details are fully redacted; no disclosed commercial terms or financial impact measurable relative to $22.1B market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.